Clinical trials: Non-Small Cell Carcinoma of Lung
Non-small Cell Lung Cancer Metastatic, EGFR G719X
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
This research study aims to explore the combination of two targeted drugs as first-line treatment for Non-Small Cell Lung Cancer (NSCLC) with uncommon EGFR mutation.
- Conditions
- Non-small Cell Lung Cancer Metastatic, EGFR G719X, EGFR L861Q, EGFR S768I
- Trial name
- IcomBine (NCT06517953)
- Testing
- Icotinib, Befotertinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Sun Yat-sen University
Cachexia; Cancer, Non Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1
The goal of this clinical trial was to compare the efficacy and safety of anamorelin HCl (the investigational drug) to that of placebo (tablet with no drug) in patients with advanced non-small cell lung cancer and cachexia…
- Trial name
- NCT03743051
- Testing
- Anamorelin Hydrochloride
- Where
- 72 sites in United States, Bulgaria and 5 more
- Volunteers
- 318 people
- Sponsor
- Helsinn Healthcare SA
Cancer, Lung, Metastasis
Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
The objective of this study is to enhance the safety profile of SAbR in ultra-central tumors of the lung (primary or metastatic) without compromising its effectiveness.
- Trial name
- NCT06712745
- Testing
- Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Carcinoma, Renal Cell, Kidney Diseases
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab.
- Conditions
- Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms
- Trial name
- NCT02543645
- Testing
- Combination of Varlilumab and Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Celldex Therapeutics
Non-small-cell Lung Cancer With Somatic EGFR Mutations
Maintaining ERBB Blockade in EGFR-mutated Lung Cancer
This study aims to compare the efficacy of afatinib maintenance with pemetrexed maintenance following induction therapy with platinum/ pemetrexed in patients with metastatic epidermal growth factor receptor (EGFR) mutated…
- Trial name
- MARBLE (NCT02488694)
- Testing
- Afatinib, Pemetrexed
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- AIO-Studien-gGmbH
Systemic Inflammatory Response Syndrome, Postoperative Pain, Acute
Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC
Lobectomy is a major, high-risk surgical procedure that in addition to one-lung ventilation (OLV) exerts a potent surgical stress response.
- Conditions
- Systemic Inflammatory Response Syndrome, Postoperative Pain, Acute, Postoperative Pain, Chronic, Infections Postoperative
- Trial name
- NCT05172739
- Testing
- Opioid-Based Anesthesia-Analgesia Strategy, Opioid-free Anesthesia-Analgesia Strategy
- Where
- Greece
- Volunteers
- 70 people
- Sponsor
- University of Crete
Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will…
- Trial name
- FLINN (NCT07355205)
- Testing
- Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT07349537
- Testing
- RMC-5127, daraxonrasib, cetuximab
- Where
- 9 sites in United States
- Volunteers
- 574 people
- Sponsor
- Revolution Medicines, Inc.
Non-Small Cell Lung Cancer
Preoperative Twice Daily Chemoradiation in Addition to Chemotherapy Prior to Surgery in Stage III Non-Small Cell Lung Cancer (NSCLC)
Patients are randomized to (arm A) 3 cycles of cisplatin/etoposide, followed by hyperfractionated radiotherapy (hfRT)with concurrent carboplatin and vindesine then surgery and, if no or R1/2-resection, additional hfRT versus (arm…
- Trial name
- NCT00176137
- Testing
- preoperative radiochemotherapy
- Volunteers
- 500 people
- Sponsor
- Heidelberg University
Non-Small Cell Lung Cancer
MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC
Despite complete (R0) resection, patients with EGFR-mutant stage IIA-IIIB non-small cell lung cancer (NSCLC) still face a substantial risk of postoperative recurrence.
- Trial name
- NCT07873086
- Testing
- Aumolertinib, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Lung Cancer
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT07645222
- Testing
- HS-20122+Aumolertinib, HS-20122+Adbrelimab, HS-20122+Adbrelimab+Platinum-based Chemo
- Where
- China
- Volunteers
- 396 people
- Sponsor
- Hansoh BioMedical R&D Company
Non-small Cell Lung Cancer
Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.
- Trial name
- NCT03700437
- Testing
- Fasting-Mimicking Diet
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Indiana University
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery
This pilot clinical trials studies azacitidine and entinostat in treating patients with newly diagnosed stage IA-IIIIA non-small cell lung undergoing surgery.
- Conditions
- Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
- Trial name
- NCT01886573
- Testing
- Azacitidine, Entinostat, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Non-small Cell Lung Carcinoma (NSCLC)
LITT and Pembrolizumab in Recurrent Brain Metastasis
This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with…
- Conditions
- Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer
- Trial name
- TORCH (NCT04187872)
- Testing
- LITT + Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced Solid Tumor
XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced…
- Trial name
- NCT07688577
- Testing
- XTX501
- Where
- 3 sites in United States
- Volunteers
- 180 people
- Sponsor
- Xilio Development, Inc.
Lung Cancer
Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab
RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment for non-small cell lung cancer may help doctors predict how patients will respond to treatment.
- Trial name
- NCT00898417
- Testing
- bevacizumab, carboplatin, paclitaxel
- Volunteers
- 90 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in…
- Conditions
- Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
- Trial name
- NCT07185997
- Testing
- Firmonertinib, EGFR-TKI inhibitor based on investigator's choice
- Where
- 141 sites in United States, Australia and 15 more
- Volunteers
- 480 people
- Sponsor
- ArriVent BioPharma, Inc.
Non-Small Cell Lung Cancer
Managed Access Programs for INC280, Capmatinib
The purpose of this registration is to list Managed Access Programs (MAPs) related to INC280, Capmatinib
- Trial name
- NCT04741789
- Testing
- Capmatinib
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
Repositioning Immunotherapy in VetArans With Lung Cancer
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
- Trial name
- RIVAL (NCT06275360)
- Testing
- Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- VA Office of Research and Development
HER2-expressing Cancers
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable)…
- Trial name
- NCT02892123
- Testing
- ZW25 (Zanidatamab), Paclitaxel, Capecitabine
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 279 people
- Sponsor
- Jazz Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.